N.N.N'-Trimethyl-α.ω-hexamethylendiamin | 1862-11-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N.N.N'-Trimethyl-α.ω-hexamethylendiamin
• 英文别名: 6-Dimethylaminohexylmethylamin；N~1~,N~1~,N~6~-Trimethylhexane-1,6-diamine；N,N',N'-trimethylhexane-1,6-diamine
• CAS: 1862-11-9
• 化学式: C₉H₂₂N₂
• 分子量: 158.287
• InChiKey: ZETYUTMSJWMKNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N.N.N'-Trimethyl-α.ω-hexamethylendiamin 在 palladium on activated charcoal 氢气 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 11.0h， 生成 4'-demethyl-4β-<2--N-methylamino>ethyl>-4-desoxypodophyllotoxin
  参考文献：
  名称：

  抗肿瘤药。3.包含4'-O-脱甲基-4-脱氧鬼臼毒素的羟基，氨基和酰胺基的4个β-烷基衍生物的合成和生物活性作为抗肿瘤剂。

  摘要：

  合成了一系列4'-O-脱甲基-4-脱氧鬼臼毒素的4个β-烷基（7-10），4个β-氨基烷基（12a-y）和4个β-酰胺基烷基衍生物（14a-g），并且评估了它们的细胞毒性，对DNA拓扑异构酶II（Topo II）的抑制作用以及微管蛋白聚合作用。12a-y和14a-g的所有衍生物均不抑制微管蛋白聚合。许多化合物表现出细胞毒性和对Topo II的抑制作用。特别是12o，12s，12t和12u会强烈抑制Topo II（分别为IC50（microM）32.5、60.9、58.8和33.6），并且对P388细胞具有很强的细胞毒性（IC50（M）1.0、4.1、3.3和分别为3.0 x 10（-9）和VP-16（IC50（microM）59.2，IC50（M）1 x 10（-8））。这些化合物的体内抗肿瘤活性几乎等于或优于VP-16（L1210，P388，

  DOI：

  10.1021/jm00064a002
• 作为产物：
  描述：

  N,N'-二甲基-1,6-己二胺 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 15.0h， 生成 N.N.N'-Trimethyl-α.ω-hexamethylendiamin
  参考文献：
  名称：

  Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist

  摘要：

  The anti-proliferative and apoptotic activities of new T-type calcium channel antagonist, 6e (BK10040) on human lung adenocarcinoma A549 cells were investigated. The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93 mu M, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. As a mode of action for cytotoxic effect of BK10040 on lung cancer (A549) cells, this cancer cell death was found to have the typical features of apoptosis, as evidenced by the accumulation of positive cells for annexin V. In addition, BK10040 triggered the activations of caspases 3 and 9, and the cleavages of poly (ADP-ribose) polymerase (PARP). Moreover, the treatment with z-VAD-fmk (a broad spectrum caspase inhibitor) significantly prevented BK10040-induced apoptosis. Based on these results, BK10040 may be used as a potential therapeutic agent for human lung cancer via the potent apoptotic activity. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.071

文献信息

• CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING
  申请人：Reiley Pharmaceuticals, Inc.

  公开号：US20150374858A1

  公开（公告）日：2015-12-31

  Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.

  披露了来自非甾体抗炎药（NSAIDs）的衍生物及其使用方法，这对于识别和定位患者疼痛感觉的病理和/或炎症部位；识别原发、继发、良性或恶性肿瘤的部位；以及诊断感染或确认或排除疑似感染非常有用。基于NSAID的偶联物含有成像基团。这些偶联物在环氧化酶表达增加的部位富集，从而揭示了前列腺素产生增加的部位，这与疼痛和炎症有关，并与肿瘤存在和/或位置有关。识别COX表达增加的区域也有助于筛查感染。
• [EN] 2-OXO-1,3-DIOXOLANE-4-CARBOXAMIDES, THEIR PREPARATION AND USE<br/>[FR] 2-OXO-1,3-DIOXOLANE-4-CARBOXAMIDES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：CONSTR RES & TECH GMBH

  公开号：WO2013092011A1

  公开（公告）日：2013-06-27

  The present invention relates to 2-oxo-1,3-dioxolane-4-carboxamides of formula (I), in which F½ can be, inter alia, an n-valent radical (n > 1), which is substituted with n-1 further 2-oxo-1,3-dioxolane-4-carboxamide groups of general formula (II), to processes for the preparation of these 2-oxo-1,3-dioxolane-4-carboxamides, to processes for the preparation of the 2-oxo-l,3-diox-olane-4-carboxylic acids of formula (III), which are suitable starting materials for the above processes, and to the use of said 2-oxo-1,3-dioxolane-4-carboxamides for the preparation of (poly)hydroxyurethanes, -hydroxycarbonates and -hydroxysulfanylformates, and also as end groups for the blocking of amines.

  本发明涉及式(I)的2-氧代-1,3-二氧杂环戊二酰胺，其中F½可以是n价基团（n > 1），该基团被n-1个进一步的通式(II)的2-氧代-1,3-二氧杂环戊二酰胺基团所取代，以及用于制备这些2-氧代-1,3-二氧杂环戊二酰胺的方法，用于制备通式(III)的2-氧代-1,3-二氧-杂环戊二酸的方法，该酸是上述方法的适用起始物质，并且用于制备（聚）羟基脲、-羟基碳酸酯和-羟基硫酰甲酸酯的所述2-氧代-1,3-二氧杂环戊二酰胺的用途，以及作为胺的阻滞末端基团。
• Compound having silsesquioxane skeleton and its polymer
  申请人：Inagaki Jyun-ichi

  公开号：US20050009982A1

  公开（公告）日：2005-01-13

  The present invention relates to a compound represented by Formula (1) and a polymer obtained using the compound: wherein R 1 is phenyl which may have substituents, Q 1 is hydrogen, halogen, alkyl having 1 to 10 carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or phenyl in which optional hydrogen may be replaced by halogen or alkyl having 1 to 5 carbon atoms, and Q 2 is a group represented by Formula (2) wherein the code < represents a bonding point with silicon, l, m, n and p are independently 0, 1, 2 or 3, A 1 to A 4 are independently a single bond, 1,4-cyclohexylene, 1,4-cyclohexenylene, a condensed ring group having 6 to 10 carbon atoms which is a divalent group, or 1,4-phenylene, Z 0 to Z 3 are independently a single bond, —CH═CR—, —C≡C—, —COO—, —OCO—, or alkylene having 1 to 20 carbon atoms, and Z 4 is a single bond, —CH═CH—, —C≡C—, —COO—, —OCO—, or alkylene having 1 to 20 carbon atoms. And Y 1 in Formula (1) is the group defined in Claim 1.

  本发明涉及一种由式（1）表示的化合物和使用该化合物获得的聚合物：其中R1是苯基，可能具有取代基；Q1是氢、卤素、具有1至10个碳原子的烷基、环丙基、环丁基、环戊基、环己基、环己烯基或苯基，其中可选的氢原子可被卤素或具有1至5个碳原子的烷基取代；Q2是由式（2）表示的基团，其中代码<表示与硅的连接点，l、m、n和p独立地为0、1、2或3，A1至A4独立地为单键、1,4-环己亚基、1,4-环己烯亚基、具有6至10个碳原子的缩合环基团，为二价基团，或1,4-苯亚基，Z0至Z3独立地为单键、—CH═CR—、—C≡C—、—COO—、—OCO—或具有1至20个碳原子的烷基，Z4为单键、—CH═CH—、—C≡C—、—COO—、—OCO—或具有1至20个碳原子的烷基。式（1）中的Y1是权利要求1中定义的基团。
• METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE BETA-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE UPSILON-HYDROXY-URETHANE UNIT
  申请人：Soules Aurélien

  公开号：US20140378648A1

  公开（公告）日：2014-12-25

  The invention relates to a method for preparing a compound comprising at least one β-hydroxy-urethane unit and/or at least one γ-hydroxy-urethane unit, consisting in reacting a compound (A) comprising at least one cyclocarbonate reactive unit with a compound (B) comprising at least one amino reactive unit (—NH2) in the presence of a catalyst. The invention also relates to the use of a catalyst comprising at least one organometallic complex and a co-catalyst chosen from the group of Lewis bases and/or tetra-alkyl ammonium salts, in order to catalyse the method of the invention. The invention relates to the technical field of preparing urethane derivatives.

  该发明涉及一种制备至少含有一个β-羟基脲基和/或至少含有一个γ-羟基脲基的化合物的方法，包括将至少含有一个环碳酸酯反应单元的化合物（A）与至少含有一个氨基反应单元（—NH2）的化合物（B）在催化剂存在下反应。该发明还涉及使用至少含有一个有机金属配合物和从Lewis碱和/或四烷基铵盐组中选择的共催化剂的催化剂，以催化该发明的方法。该发明涉及制备脲基衍生物的技术领域。
• [EN] IMPROVEMENTS IN OR RELATING TO CURATIVES<br/>[FR] AMÉLIORATIONS APPORTÉES OU SE RAPPORTANT À DES AGENTS DE DURCISSEMENT
  申请人：HEXCEL COMPOSITES LTD

  公开号：WO2020216688A1

  公开（公告）日：2020-10-29

  The host compound in a clathrate is an amino or hydroxyl containing aromatic phosphorous compound, clathrates containing a resin curative and their use in curable resin compositions to produce moulded articles particularly fibre reinforced articles.

  在蛛网状化合物中的宿主化合物是一种含氨基或羟基的芳香磷化合物，这些蛛网状化合物含有树脂固化剂，可用于可固化树脂组合物中，以生产模塑制品，特别是纤维增强制品。